Document is current
Any future updates will be listed below
-
Authors
Fromentin, Rémi
DaFonseca, Sandrina
Costiniuk, Cecilia T.
El-Far, Mohamed
Procopio, Francesco Andrea
Hecht, Frederick M. http://orcid.org/0000-0002-5782-1171
Hoh, Rebecca
Deeks, Steven G. http://orcid.org/0000-0001-6371-747X
Hazuda, Daria J.
Lewin, Sharon R.
Routy, Jean-Pierre http://orcid.org/0000-0001-9897-7589
Sékaly, Rafick-Pierre
Chomont, Nicolas http://orcid.org/0000-0001-9747-5018
- License Information
-
More Information
Article History
Received: 1 November 2018
Accepted: 23 January 2019
First Online: 18 February 2019
Competing Interests
: D.J.H. is an employee and shareholder of Merck & Co., Inc., manufacturer of pembrolizumab. S.G.D. has received grant support from Gilead, Merck, and ViiV. He has consulted from AbbVie, Janssen and Shionogi. He is a member of the scientific advisory boards for Enochian Biosciences and BryoLogyx. N.C. has received grant support from Merck. The remaining authors declare no competing interests.
